Kathleen A. Rickard - Aug 3, 2023 Form 4 Insider Report for Verona Pharma plc (VRNA)

Signature
/s/ Claire Poll, Attorney-in-fact for Kathleen A. Rickard
Stock symbol
VRNA
Transactions as of
Aug 3, 2023
Transactions value $
-$202,576
Form type
4
Date filed
8/7/2023, 09:19 PM
Previous filing
Aug 3, 2023
Next filing
Oct 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Sale -$73.3K -28.8K -0.97% $2.55* 2.92M Aug 3, 2023 Direct F1, F2, F3
transaction VRNA Ordinary Shares Sale -$55.5K -21.8K -0.75% $2.54* 2.9M Aug 3, 2023 Direct F1, F4, F5
transaction VRNA Ordinary Shares Sale -$69.8K -27.9K -0.96% $2.50* 2.87M Aug 4, 2023 Direct F1, F4, F5
transaction VRNA Ordinary Shares Sale -$3.95K -1.6K -0.06% $2.47* 2.87M Aug 7, 2023 Direct F1, F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 These sales were effected pursuant to a Rule 10b5-1 instruction entered into on May 14, 2021 solely with the intent to cover taxes in connection with the vesting of certainly previously reported Restricted Share Units.
F3 The price reported represents a weighted average sale price of the ADSs divided by eight (8). These shares were sold in multiple transactions at prices ranging from $2.485 to $2.6488, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 These sales were effected pursuant to a Rule 10b5-1 instruction entered into on May 14, 2021 solely with the intent to cover taxes in connection with the vesting of certainly previously reported Restricted Share Units.
F5 The price reported represents the sale price of the ADSs divided by eight (8).
F6 Consists of (i) 1,551,792 Ordinary Shares underlying RSUs (which are represented by 193,974 ADSs); and (ii) 1,320,736 Ordinary Shares underlying 165,092 ADSs.